

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 561 597 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
02.01.1997 Bulletin 1997/01

(51) Int Cl.⁶: **C07D 487/04, C07F 9/10,**
A61K 31/40
// (C07D487/04, 209:00, 209:00)

(21) Application number: **93301955.6**

(22) Date of filing: **15.03.1993**

(54) **New derivatives of physostigmine, their use and pharmaceutical formulations containing them**
Physostigmin-Derivate, ihre Verwendung und sie enthaltende pharmazeutische Formulierungen
Dérivés de physostigmine, leur usage et formulations pharmaceutiques les contenant

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: **16.03.1992 GB 9205670**

(43) Date of publication of application:
22.09.1993 Bulletin 1993/38

(73) Proprietor: **INDENA S.p.A.**
20139 Milano (IT)

(72) Inventor: **Bombardelli, Ezio**
I-Milan 20141 (IT)

(74) Representative: **Ritter, Stephen David et al**
Mathys & Squire
100 Grays Inn Road
London WC1X 8AL (GB)

(56) References cited:

EP-A- 0 298 202	EP-A- 0 350 672
EP-A- 0 354 594	EP-A- 0 441 279
EP-A- 0 513 703	GB-A- 2 005 259

- **CHEMICAL ABSTRACTS**, vol. 112, no. 22, 28 May 1990, Columbus, Ohio, US; abstract no. 204732f, page 400 ;
- **CHEMICAL ABSTRACTS**, vol. 109, no. 21, 21 November 1988, Columbus, Ohio, US; abstract no. 190633y, page 740 ;

Remarks:


The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

The present invention relates to new derivatives of physostigmine, to processes for their production and to novel pharmaceutical compositions and dosage forms containing them. The invention further relates to the therapeutic use of the novel physostigmine derivatives of the invention in the treatment of syndromes relates to changes in cerebral metabolism in the elderly.

Physostigmine (I) is a well-known alkaloid which has been used as a myotic agent since the beginning of this century. The substance has now almost completely been abandoned for its original therapeutic use. However over the last 15 years it has been found that physostigmine's significant anticholinesterase activity makes it particularly valuable in the treatment of Alzheimer's disease and the severe effects of various forms of senile dementia, since it improves the cholinergic deficit found in the brain of affected patients.




A number of clinical studies (Davis, Am. J. Psychiat., 139, 1421, 1982; Jotkowitz, Ann. Neurol., 14, 690, 1983; Davis, New Engl. J. Med., 308, 721, 1983) have shown that the intravenous administration of repeated daily doses of physostigmine produced significant improvements in memory. It was also found that when the alkaloid is administered subcutaneously or by mouth, it is degraded rapidly, with the result that treatment must be repeated at short intervals. A further disadvantage of both the intravenous and subcutaneous routes of administration is that both are uncomfortable and impractical for use over long periods.

It is known that physostigmine is capable of passing through the blood-brain barrier to reach the nuclei where it exerts its effect. The physostigmine derivatives currently used for this purpose include salts such as those traditionally described in pharmacopeias for formulating basic alkaloids. These include the salicylate, the sulphate or the nitrate, though more lipophilic derivatives of physostigmine, such as the heptyl derivative (IT 047780) or its analogues have been developed.

Other derivatives include those described in EP-A-0 298 202. This document describes derivatives of physostigmine in which the methyl carbamate group is replaced by a C₂₋₁₂ alkyl carbamate group and claims organic salts of such derivatives with organic acids selected from tartaric, maleic and citric acids.

A further class of physostigmine derivatives are described in US 7 166 824, including (-)-N(1)-norphysostigmine, (-)-N(1)-alkylphysostigmine and (-)-N(1)-phenylethylphysostigmine.

The compounds of US 7 166 824 are represented by the formula



wherein

R¹ = H, R² = CH₃


R¹ = Bz, R² = CH₃

R¹ = Bz, R² = OH

R¹ = Bz, R² = OCONH-CH₃

R¹ = H, R² = CONH-CH₃

R¹ = CH₂=CH-CH₂, R² = CONHCH₃




JP-0-1279830 discloses the use of physostigmine-containing compositions wherein pentaenoic and/or hexaenoic acids and phosphatidyl choline are included as excipients.

EP-A-0 441 279 describes complexes formed between natural or synthetic phospholipids and bilobalide and their therapeutic application as anti-inflammatory agents.

A disadvantage of the salts of physostigmine and the derivatives and compositions described hitherto is that they have an extremely short half-life and are eliminated from the blood completely within 2 hours. Physostigmine is also a highly toxic product with a small therapeutic margin, and the doses administered by conventional routes must therefore necessarily be low. We have now attempted to rationalize the use of physostigmine by devising new salts and also by administering the drug in such a way that it gains a more direct access to the brain for prolonged periods in non-toxic concentrations. In making this invention, it was surprisingly found that certain lipophilic salts of physostigmine, which are specifically the subject of the invention, when administered in an appropriate manner, can prolong the mean life of the alkaloid, so bringing significant therapeutic advantages.

According to one aspect of the present invention, there are provided salts of physostigmine, or of a pharmacologically acceptable derivative thereof having anticholinesterase activity, and a phosphatidic acid.

The salts of the invention may be represented by the formula



wherein

PS represents a cation derived from physostigmine, or from a pharmacologically acceptable derivative thereof having anticholinesterase activity,

PA represents a phosphatidic acid or a mixture of different phosphatidic acids, and

x:y is from 2:1 to 1:2.

Preferably the ratio x:y is from 1.2:1 to 1:1.2, most preferably from 1.1:1 to 1:1.1.

In the above formula, PS is preferably physostigmine, but it can also represent a pharmacologically acceptable derivative of physostigmine, for example one of those described in IT 047780, EP 0 298 202 and US 7 166 824.

The term "phosphatidic acid" as used herein, represents a compound having the formula



wherein R_1 and R_2 , which may be the same or different, each represents a C_{10-24} alkyl group, a C_{10-24} alkenyl group, or a C_{10-24} alkadienyl group. Said groups respectively may be represented by the formulae $\text{C}_n\text{H}_{2n+1}$, $\text{C}_n\text{H}_{2n-1}$ or $\text{C}_n\text{H}_{2n-3}$ wherein n is from 10 to 24.

Preferably n is from 15 to 24, most preferably 15 or 17.

The salts of the invention may be prepared by a process comprising salification of (a) physostigmine, or a pharmacologically acceptable derivative thereof, with (b) one or more phosphatidic acids, each of said reactants (a) and (b) being in the free form or in the form of a salt-forming derivative. The salification is preferably carried out in a solvent for both reactants. Such processes form further aspects of the invention.

The solvent is preferably selected from halogenated hydrocarbons, ketones, ethers and mixtures thereof.

The invention further provides pharmaceutical compositions comprising a salt of physostigmine, or of a pharmacologically acceptable derivative of physostigmine having anticholinesterase activity, and a phosphatidic acid, preferably one of the preferred salts defined above and a pharmaceutically acceptable excipient. The compositions are preferably provided as sustained release pharmaceutical dosage forms capable of releasing the pharmacologically active ingredient(s) over a period of time.

Such sustained release pharmaceutical dosage forms are preferably adapted to release the pharmaceutically active ingredient(s) trans-cutaneously, for example by being presented in the form of a cutaneous patch, plaster or bandage.

As indicated, the products of the present invention, namely new salts of physostigmine or of a pharmacologically acceptable derivative thereof having anticholinesterase activity, may be obtained by salification in protic or non-protic solvents of the alkaloid in the form of the base or the salt with anions of weak organic acids, with natural or synthetic phosphatidic acids, having saturated or unsaturated, homogeneous or mixed acyl chains.

The salts that can be derived from natural phosphatidic acids of vegetable origin are of particular interest. Such phosphatidic acids can be separated from common plants widely used for food such as soya, peanuts, etc. The salts may be obtained by reacting a stoichiometric quantity of the alkaloid with a stoichiometric quantity of the chosen phosphatidic acid (1M:1M).

Once formed, the salts are highly soluble in non-protic solvents and therefore exhibit pronounced lipophilia. This is believed to be due to the fact that the mobility of the lipid chains enables them to wind round the more polar nucleus of the new salts. The transcutaneous and transepidermal absorption of the salts of the invention is far superior to that of the salts used hitherto.

Given that drugs for the treatment of senile dementia must act principally in the cerebral cortex, which contains the basal ganglia that control the body's fundamental neuronal responses, it would be extremely valuable if drugs could be sent directly to the brain in a specific way without hepatic by-pass and without their having to act on other organs and body systems, thereby producing toxic effects.

It has been found that the highly lipophilic salts of alkaloids with an adrenergic or anticholinesterase action (which constitute one of the subjects of the present invention) enables this specific object to be achieved. When applied in controlled-release formulations according to the invention at the base of the neck close to the bifurcation of the branches of the internal carotid and common carotid arteries or below the ear close to the external carotid artery or the anterior auricular or posterior occipital artery, it has been found to be possible to maintain high levels of the drug in the brain for prolonged periods, as is necessary in the treatment of chronic diseases.

When the salts of phosphatidic acids with physostigmine or with a pharmacologically acceptable derivative thereof having anticholinesterase according to the invention come into contact with water they form microdispersions of a liposomal type that interact rapidly with the cell structures or diffuse freely through the tissues where they can easily reach the lumen of the arteries, whence they travel to the site of action.

The new salts can be applied to the sites described above in dosages between 0.5 and 50 mg given as one or more daily doses depending on the individual receptor response. It is clear that if consistent results are to be obtained in a chronic degenerative disease there must be a constant supply of the drug to the target organ in quantities sufficient to produce the required effect. This has been achieved using salts according to the invention.

Controlled-release transcutaneous pharmaceutical forms have proved suitable for the administration of the new salts of the invention since they enable the drug to be directed to the target organ with minimal involvement of the peripheral organs. Controlled-release plasters have proved particularly effective for this purpose since between 0.5 and 50 mg physostigmine phosphatide can be incorporated in the reservoir. Liposomal forms of the same salt applied in the form of lipogels, with or without the presence of conventional phospholipids, have also proved effective. The plaster form has proved extremely practical for long-term use, as is necessary in treating Alzheimer's disease and other forms of senile dementia. However, the drug can also be incorporated and administered in other conventional forms such as tablets, oily solutions, suppositories, etc.

The examples set out below serve to illustrate the invention without in any way limiting its scope.

Example I: Preparation of physostigmine dipalmitoyl glyceryl phosphatide

2.75 g physostigmine base are dissolved in 15 ml methylene chloride with stirring, then 6.48 g dipalmitoyl glyceryl phosphatidic acid are added at ambient temperature. When the reagents have dissolved completely, the solution in methylene chloride is evaporated to dryness under vacuum at a temperature not exceeding 40°C until the solvent has been completely eliminated. The residue is dispersed in n-hexane at 5°C and filtered.

This yields 9.75 g of a white solid with the following characteristics: m.p. 62.2°C [α]_D = 45° (conc = 1% in CHCl₃); ³¹P-NMR 2.23 3.15

Example II: Preparation of a salt of physostigmine with phosphatidic reagent

2.75 g physostigmine base are dissolved in 15 ml methylene chloride with stirring and 7 g phosphatidic acid derived from hydrogenated soya and having a natural ratio of fatty acids and a mean molecular weight determined by acid-base titration of 698, are added. When the reagents have dissolved completely, the solution in methylene chloride is evaporated to dryness under vacuum at a temperature not exceeding 40°C until the solvent has been completely eliminated. The residue is dispersed in n-hexane at 5°C and filtered. This yields 9.75 g of a white solid with the following characteristics: m.p. 55.8°C $[\alpha]_D = +47.7$ (conc = 1% CHCl₃)
³¹P-NMR 2.27 3.22

Example III: Preparation of plasters for transdermal absorption containing the physostigmine salt of hydrogenated soya phosphatidic acid


The physostigmine salt is incorporated in an adhesive mass that controls the release of the drug and has the following composition:

physostigmine phosphatidate	50 mg
lactose	398 mg
saturated triglycerides	22 mg
polyisobutene	220 mg
hydrogenated colophony	195 mg
polyalkadiene	195 mg

The transdermal plaster is made up of three layers, namely a backing sheet, an adhesive film containing the active principle built up by applying several coatings, and a cover sheet. The drug is released over a period of 24 h to ensure continuous administration.


Claims

1. A salt of physostigmine, or a pharmacologically acceptable derivative thereof having anticholinesterase activity, and a phosphatidic acid having the formula



wherein R₁ and R₂, which may be the same or different each represents a C₁₀₋₂₄ alkyl group, a C₁₀₋₂₄ alkenyl group, or a C₁₀₋₂₄ alkadienyl group.

2. A salt according to Claim 1 having the formula



wherein

PS represents a cation derived from physostigmine or a pharmacologically acceptable derivative thereof having anticholinesterase activity,


PA represents a phosphatidic acid or a mixture of different phosphatidic acids, and

x:y is from 2:1 to 1:2.

3. A salt according to Claim 2 wherein x:y is from 1.2:1 to 1:1.2, preferably from 1.1:1 to 1:1.1.
4. A salt according to Claim 2 or Claim 3 wherein PS is physostigmine.
5. A salt according to any preceding claim wherein R_1 and R_2 , which may be the same or different each represents a C_{15-24} alkyl group, a C_{15-24} alkenyl group, or a C_{15-24} alkadienyl group.
6. A salt according to Claim 5 wherein R_1 and R_2 , which may be the same or different each represents a C_{15} or 17 alkyl group, a C_{15} or 17 alkenyl group, or a C_{15} or 17 alkadienyl group.
7. A method for producing a salt as claimed in any preceding claim which comprises reacting physostigmine or a pharmacologically acceptable salt thereof, with a phosphatidic acid, said reaction being carried out in a solvent for both reactants.
8. A method according to Claim 7 wherein the solvent is selected from halogenated hydrocarbons, ketones, ethers and mixtures thereof.
9. A pharmaceutical composition comprising a salt according to any of Claims 1 to 6 and a pharmaceutically acceptable excipient.
10. A sustained release pharmaceutical dosage form capable of releasing a pharmacologically active substance over a period of time, characterised in that the pharmaceutically active substance is a salt as claimed in any of Claims 1 to 6.
11. A sustained release pharmaceutical dosage form as claimed in Claim 10, adapted to release the pharmaceutically active substance trans-cutaneously.
12. A sustained release pharmaceutical dosage form according to Claim 11 in the form of a cutaneous patch, plaster or bandage.
13. The use of a salt of physostigmine, or a pharmacologically acceptable derivative according to any of Claims 1 to 6 thereof having anticholinesterase activity, and a phosphatidic acid in the manufacture of a pharmaceutical composition for treating senile dementia and Alzheimer's disease.

Patentansprüche

1. Salz aus Physostigmin oder einem pharmakologisch verträglichen Derivat davon mit Anticholinesterase-Aktivität, und einer Phosphatidsäure mit der Formel



worin R_1 und R_2 , die gleich oder unterschiedlich sein können, jeweils einen C_{10-24} -Alkylrest, einen C_{10-24} -Alkenylrest oder einen C_{10-24} -Alkadienylrest bedeuten.

2. Salz nach Anspruch 1 mit der Formel



worin

PS ein von Physostigmin oder einem pharmakologisch verträglichen Derivat davon abgeleitetes Kation mit Anticholinesterase-Aktivität bedeutet,

PA eine Phosphatidsäure oder ein Gemisch unterschiedlicher Phosphatidsäuren bedeutet, und $x:y$ 2:1 bis 1:2 beträgt.

3. Salz nach Anspruch 2, worin $x:y$ 1,2:1 bis 1:1,2, bevorzugt 1,1:1 bis 1:1,1, beträgt.

4. Salz nach Anspruch 2 oder 3, worin PS Physostigmin ist.

5. Salz nach einem der vorstehenden Ansprüche, worin R_1 und R_2 , die gleich oder verschieden sein können, jeweils einen C_{15-24} -Alkylrest, einen C_{15-24} -Alkenylrest oder einen C_{15-24} -Alkadienylrest bedeuten.

6. Salz nach Anspruch 5, worin R_1 und R_2 , die gleich oder verschieden sein können, jeweils einen C_{15} oder $_{17}$ -Alkylrest, einen C_{15} oder $_{17}$ -Alkenylrest oder einen C_{15} oder $_{17}$ -Alkadienylrest bedeuten.

7. Verfahren zur Herstellung eines Salzes nach einem der vorstehenden Ansprüche, wobei man Physostigmin oder ein pharmakologisch verträgliches Salz davon mit einer Phosphatidsäure umsetzt, wobei die Reaktion in einem Lösungsmittel für beiden Reaktanten durchgeführt wird.

8. Verfahren nach Anspruch 7, wobei das Lösungsmittel aus halogenierten Kohlenwasserstoffen, Ketonen, Ethern und Gemischen davon ausgewählt wird.


9. Pharmazeutische Zusammensetzung, umfassend ein Salz nach einem der Ansprüche 1 bis 6, und ein pharmazeutisch verträgliches Exzipiens.

10. Pharmazeutische Dosierungsform mit verzögerter Freisetzung, die eine pharmakologisch aktive Substanz über eine Zeitspanne freisetzen kann, dadurch gekennzeichnet, daß die pharmazeutisch aktive Substanz ein Salz nach einem der Ansprüche 1 bis 6 ist.

11. Pharmazeutische Dosierungsform mit verzögerter Freisetzung nach Anspruch 10, die der transkutanen Freisetzung der pharmazeutisch aktiven Substanz angepaßt ist.
12. Pharmazeutische Dosierungsform mit verzögerter Freisetzung nach Anspruch 11, in Form eines Hautflecken, eines Pflasters oder einer Bandage.
13. Verwendung eines Salzes aus Physostigmin oder einem pharmakologisch verträglichen Derivat davon nach einem der Ansprüche 1 bis 6 mit Anticholinesterase-Aktivität und Phosphatidsäure zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung der senilen Demenz und der Alzheimer-Krankheit.


Revendications

1. Sel de physostigmine, ou dérivé de celle-ci, pharmaceutiquement acceptable, ayant une activité anticholinestérase, et acide phosphatidique de formule :



dans laquelle R_1 et R_2 qui peuvent être identiques ou différents représentent chacun un groupe alkyle C_{10-24} , un groupe alkényle C_{10-24} , ou un groupe alkadiényle C_{10-24} .

2. Sel selon la revendication 1, ayant la formule :



dans laquelle :

- PS représente un cation dérivé de la physostigmine, ou d'un dérivé de celle-ci, pharmaceutiquement acceptable, ayant une activité anti-cholinestérase,
- PA représente un acide phosphatidique, ou un mélange de différents acides phosphatidiques. et x/y est compris entre 2/1 et 1/2.

3. Sel selon la revendication 2, dans lequel x/y est compris entre 1,2/1 et 1/1,2, de préférence, entre 1,1/1 et 1/1,1.
4. Sel selon la revendication 2, ou la revendication 3, dans lequel PS représente physostigmine.
5. Sel selon l'une quelconque des revendications précédentes, dans lequel R_1 et R_2 , qui peuvent être identiques ou différents, représentent chacun un groupe alkyle C_{15-24} , un groupe alkényle C_{15-24} , ou un groupe alkadiényle C_{15-24} .
6. Sel selon la revendication 5, dans lequel R_1 et R_2 , qui peuvent être identiques ou différents, représentent chacun

un groupe alkyle C₁₅ ou 17, un groupe alkényle C₁₅ ou 17, ou un groupe alkadiényle C₁₅ ou 17.

7. Méthode de production d'un sel selon l'une quelconque des revendications précédentes, qui comprend la réaction de la physostigmine, ou d'un sel de celle-ci, pharmaceutiquement acceptable, avec un acide phosphatidique, ladite réaction étant effectuée dans un solvant des deux réactants.
8. Méthode selon la revendication 7, dans laquelle le solvant est choisi parmi les hydrocarbures halogénés, les cétones, les éthers, et les mélanges de ceux-ci.
9. Composition pharmaceutique comprenant un sel selon l'une quelconque des revendications 1 à 6, et un excipient pharmaceutiquement acceptable.
10. Forme pharmaceutique à libération prolongée, capable de libérer une substance pharmacologiquement active pendant une certaine période de temps, caractérisée en ce que la substance pharmacologiquement active est un sel selon l'une quelconque des revendications 1 à 6.
11. Forme pharmaceutique à libération prolongée selon la revendication 10, adaptée à la libération de la substance pharmacologiquement active par voie transcutanée.
12. Forme pharmaceutique à libération prolongée selon la revendication 11, sous la forme d'un timbre, emplâtre, ou bandage cutané.
13. Utilisation d'un sel de physostigmine, ou d'un dérivé de celle-ci, pharmaceutiquement acceptable, selon l'une quelconque des revendications 1 à 6, ayant une activité anticholinestérase, et d'un acide phosphatidique, dans la fabrication d'une composition pharmaceutique pour le traitement de la démence sénile, et de la maladie d'Alzheimer.

REGISTER ENTRY FOR EP0561597

European Application No EP93301955.6 filing date 15.03.1993

Priority claimed:

16.03.1992 in United Kingdom - doc: 9205670

Designated States BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE AT

Title NEW DERIVATIVES OF PHYSOSTIGMINE, THEIR USE AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM.

Applicant/Proprietor

INDENA S.P.A., Via Ripamonti, 99, I-20141 Milano, Italy

[ADP No. 50156546001]

Inventor

EZIO BOMBARDELLI, via Ripamonti 99, I-Milan 20141, Italy

[ADP No. 61244679001]

Classified to

C07D A61K C07F

Address for Service

MATHYS & SQUIRE, 100 Grays Inn Road, LONDON, WC1X 8AL, United Kingdom

[ADP No. 00001081001]

EPO Representative

STEPHEN DAVID RITTER, Mathys & Squire 10 Fleet Street, London EC4Y 1AY,

United Kingdom

[ADP No. 50530237001]

Publication No EP0561597 dated 22.09.1993

Publication in English

Examination requested 10.09.1993

Patent Granted with effect from 02.01.1997 (Section 25(1)) with title NEW DERIVATIVES OF PHYSOSTIGMINE, THEIR USE AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM

26.07.1996 Notification from EPO of change of Applicant/Proprietor details from

INDENA S.P.A., Via Ripamonti, 99, I-20141 Milano, Italy

[ADP No. 50156546001]

to

INDENA S.P.A., viale Ortles, 12, 20139 Milano, Italy

[ADP No. 50156546003]

Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

31.08.1996 MATHYS & SQUIRE, 100 Grays Inn Road, LONDON, WC1X 8AL, United Kingdom

[ADP No. 00001081001]

registered as address for service

Entry Type 8.11 Staff ID. SB2 Auth ID. AO

29.11.1996 Notification from EPO of change of EPO Representative details from
STEPHEN DAVID RITTER, Mathys & Squire 10 Fleet Street, London EC4Y
1AY, United Kingdom [ADP No. 50530237001]
to
STEPHEN DAVID RITTER, Mathys & Squire 100 Grays Inn Road, London
WC1X 8AL, United Kingdom [ADP No. 50530237001]
Entry Type 25.14 Staff ID. RD06 Auth ID. EPT

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

12/02/97

14:01:33
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER EP0561597 .

PROPRIETOR(S)

INDENA S.p.A., *see entry* viale Ortles, 12, 20139 Milano, Italy *see Or*

DATE FILED 15.03.1993 .

DATE GRANTED 02.01.1997 .

DATE NEXT RENEWAL DUE 02.04.1997

DATE NOT IN FORCE

DATE OF LAST RENEWAL

YEAR OF LAST RENEWAL 00

STATUS PATENT IN FORCE

**** END OF REPORT ****